The effect of aminophylline administration on 99mTc-MIBI lung and liver uptake in patients with or without myocardial ischemia.
This work aims to analyze the influence of aminophylline in the pulmonary and hepatic uptake of 99mTc-methoxyisobutil isonitrile (99mTc-MIBI). 72 patients were studied and a myocardial perfusion (MPS) single photon emission computed tomography (SPECT) with 99mTc-MIBI was carried out after the administration of dipyridamole. According to the MPS, the patients were classified into 2 groups: Group A: 45 patients without myocardial ischemia and Group B: 27 with ischemia. Each group was divided into 2 subgroups according to whether they had (I) or had not (II) received intravenous aminophylline. The dipyridamole was administered for 4 minutes at a dose of 0.56 mg/kg. If the patients presented any complication, intravenous aminophylline was administered. At 30 minutes p.i., planar images were obtained during a scintigraphy in the interior projection after the injection of 99mTc-MIBI. The regions of interest in the heart, hepatic cupula, and most active area of the left lung were outlines and the activity rates were calculated: lung/heart (LHR) and liver/heart (LivHR). No statistically significant differences were observed in the uptake of 99mTc-MIBI between subgroups I and II. However, the LHR rates in both subgroups were significantly lower in the patients with normal myocardial perfusion than in the patients with ischemia: LHR group A1 vs B1: 0. 32 +/- 0.08 vs 0.36 +/- 0.06, p = 0.03; group AII vs BII 0.31 +/- 0. 07 vs 0.35 +/- 0.07, p = 0.01 respectively. In conclusion, the administration of aminophylline, after the infusion of dipyridamole for MPS, does not modify the pulmonary or hepatic uptake of 99mTc-MIBI.
Yüksel
M
M
Trakya University Faculty of Medicine Department of Nuclear Medicine, Edirne. Turkey. mahmuty@trakya.edu.tr
Durmus Altun
G
G
Altun
A
A
Berkarda
S
S
D000328:Adult; D000368:Aged; D000628:Aminophylline / Q000494:pharmacology*; D000704:Analysis of Variance; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004176:Dipyridamole; D005260:Female; D006801:Humans; D008099:Liver / Q000378:metabolism*; D008168:Lung / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000378:metabolism*; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D017256:Technetium Tc 99m Sestamibi / Q000493:pharmacokinetics*; D015899:Tomography, Emission-Computed, Single-Photon; D014665:Vasodilator Agents
D002316:Cardiotonic Agents; D019275:Radiopharmaceuticals; D014665:Vasodilator Agents; D000628:Aminophylline; D004176:Dipyridamole; D017256:Technetium Tc 99m Sestamibi